Roth Capital Lowers Capricor Therapeutics (NASDAQ:CAPR) Price Target to $12.00

Capricor Therapeutics (NASDAQ:CAPR) had its target price dropped by equities research analysts at Roth Capital from $31.00 to $12.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price objective would suggest a potential upside of 67.13% from the stock’s previous close.

A number of other equities analysts have also commented on the stock. Alliance Global Partners initiated coverage on shares of Capricor Therapeutics in a research report on Monday, June 30th. They set a “buy” rating and a $20.00 target price on the stock. Oppenheimer cut their target price on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a research report on Monday, June 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Finally, B. Riley assumed coverage on shares of Capricor Therapeutics in a research report on Thursday, June 26th. They set a “buy” rating and a $21.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $22.56.

Capricor Therapeutics Stock Down 2.8%

CAPR stock opened at $7.18 on Monday. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40. The company has a fifty day simple moving average of $10.27 and a two-hundred day simple moving average of $12.01. The firm has a market capitalization of $327.98 million, a P/E ratio of -5.06 and a beta of 0.82.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The business had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. During the same quarter last year, the business earned ($0.31) EPS. As a group, analysts anticipate that Capricor Therapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds have recently modified their holdings of CAPR. Bank of New York Mellon Corp boosted its stake in Capricor Therapeutics by 32.6% during the fourth quarter. Bank of New York Mellon Corp now owns 84,027 shares of the biotechnology company’s stock worth $1,160,000 after buying an additional 20,638 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Capricor Therapeutics by 51.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock valued at $1,536,000 after purchasing an additional 37,868 shares during the period. AlphaQuest LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at approximately $78,000. Swiss National Bank purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at approximately $930,000. Finally, Intech Investment Management LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at approximately $228,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.